These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2253 related articles for article (PubMed ID: 33121495)

  • 1. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
    Du C; Lv C; Feng Y; Yu S
    J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
    Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
    Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
    [No Abstract]   [Full Text] [Related]  

  • 4. m
    Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
    Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
    Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
    J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3/YTHDF2 m
    Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
    J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
    Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
    Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m
    Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
    J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export.
    Li D; Cai L; Meng R; Feng Z; Xu Q
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
    Yang X; Zhang S; He C; Xue P; Zhang L; He Z; Zang L; Feng B; Sun J; Zheng M
    Mol Cancer; 2020 Feb; 19(1):46. PubMed ID: 32111213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m
    Ren M; Pan H; Zhou X; Yu M; Ji F
    J Transl Med; 2024 Jun; 22(1):584. PubMed ID: 38902717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METTL3-dependent N
    Chien CS; Li JY; Chien Y; Wang ML; Yarmishyn AA; Tsai PH; Juan CC; Nguyen P; Cheng HM; Huo TI; Chiou SH; Chien S
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33579825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3-Mediated m
    Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
    Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
    Song D; Wang Q; Yan Z; Su M; Zhang H; Shi L; Fan Y; Zhang Q; Yang H; Zhang D; Liu Q
    Biol Direct; 2024 Jun; 19(1):44. PubMed ID: 38849910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.